Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 9/20 | 0.47 |
| ▸ | CDK1 | P06493 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998609 | 0.94 | DYRK2 (0.51) | DYRK2CDK2CDK1KCNH2CDK6 | |
| SCHEMBL4261417 | 0.93 | DYRK2 (0.49) | DYRK2CDK2CDK1KCNH2CDK6 | |
| SCHEMBL3942238 | 0.92 | CDK2 (0.57) | DYRK2CDK2CDK1KCNH2FLT3 | |
| SCHEMBL4259586 | 0.91 | CDK2 (0.48) | DYRK2CDK2CDK1KCNH2FLT3 | |
| SCHEMBL4408272 | 0.91 | CDK2 (0.51) | DYRK2CDK2CDK1KCNH2FLT3 | |
| SCHEMBL4261901 | 0.91 | CDK2 (0.49) | DYRK2CDK2CDK1KCNH2FLT3 | |
| SCHEMBL4262151 | 0.91 | DYRK2 (0.47) | DYRK2CDK2CDK1KCNH2FLT3 | |
| Hydrochloric Acid SCHEMBL4254767 | 0.90 | CDK2 (0.57) | DYRK2CDK2CDK1KCNH2CDK6 | |
| SCHEMBL4268947 | 0.90 | CDK2 (0.47) | DYRK2CDK2CDK1KCNH2FLT3 | |
| SCHEMBL4262678 | 0.90 | CDK2 (0.48) | DYRK2CDK2CDK1KCNH2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| US-20080188502-A1 | New Compounds I | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188502-A1 | New Compounds I | SLC10A1, REN, SLC5A1 | DYRK2 4299/4885CDK2 3536/4885CDK1 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.